A new agent in the family of antibody-drug conjugates
Mené sur 39 puis 146 patients atteints d'une tumeur solide de stade localement avancé ou métastatique HER2+, cet essai de phase I évalue la dose maximale tolérée et l'efficacité, du point de vue de la proportion de patients obtenant une réponse objective, du trastuzumab duocarmazine, un nouveau conjugué anticorps-médicament ciblant HER2
Amplification of the HER2 gene occurs in approximately 15% of breast cancers, defining HER2-positive disease. Patients whose tumour overexpresses the HER2 receptor derive benefit from trastuzumab-based treatments. The emergence of antikinase treatments (eg, neratinib and lapatinib) and other antibodies (eg, pertuzumab) that target the HER2 receptor have enhanced this class of drugs and have substantially improved outcomes for patients with HER2-positive breast cancer.
The Lancet Oncology , commentaire, 2018